Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $2.37 and traded as high as $2.49. Oramed Pharmaceuticals shares last traded at $2.49, with a volume of 158,176 shares.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on the stock. StockNews.com lowered shares of Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, December 2nd. HC Wainwright reiterated a "neutral" rating on shares of Oramed Pharmaceuticals in a report on Monday, September 9th.
Check Out Our Latest Research Report on Oramed Pharmaceuticals
Oramed Pharmaceuticals Stock Down 0.8 %
The company has a market capitalization of $99.57 million, a P/E ratio of 22.45 and a beta of 1.70. The business has a 50 day moving average of $2.37 and a 200 day moving average of $2.39.
Institutional Trading of Oramed Pharmaceuticals
A number of large investors have recently made changes to their positions in ORMP. BML Capital Management LLC increased its position in shares of Oramed Pharmaceuticals by 62.1% during the 3rd quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company's stock valued at $5,334,000 after purchasing an additional 837,153 shares during the last quarter. Murchinson Ltd. boosted its stake in Oramed Pharmaceuticals by 23.2% during the second quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company's stock worth $4,369,000 after buying an additional 320,495 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new position in Oramed Pharmaceuticals during the third quarter valued at $272,000. Renaissance Technologies LLC raised its stake in shares of Oramed Pharmaceuticals by 89.0% in the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company's stock valued at $593,000 after acquiring an additional 108,700 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of Oramed Pharmaceuticals in the 2nd quarter worth about $40,000. 12.73% of the stock is currently owned by institutional investors.
Oramed Pharmaceuticals Company Profile
(
Get Free Report)
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
Further Reading
Before you consider Oramed Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.
While Oramed Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
